Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL601223 | 0.98 | ITGB3 (0.44) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Leucine SCHEMBL3814957 | 0.92 | ITGB3 (0.45) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL7217344 | 0.91 | MAPT (0.53) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Leucine SCHEMBL1414045 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL7161574 | 0.87 | NPSR1 (0.48) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL3194343 | 0.86 | ITGB3 (0.43) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL1406185 | 0.86 | GAA (0.38) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| SCHEMBL31238101 | 0.85 | PSMB5 (0.54) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 | |
| Alanine SCHEMBL3470608 | 0.82 | NTSR1 (0.39) | NTSR1MEN1KMT2AKEAP1NFE2L2 | |
| SCHEMBL5098994 | 0.80 | NTSR1 (0.58) | ITGB3ITGAVNTSR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | claimed |
| EP-1355910-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | claimed |
| EP-2251344-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-17 | — | — | EP | claimed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | claimed |
| US-7109323-B2 | lyophilization of an aqueous mixture comprising a boronic add compound and a compound having at least two hydroxyl groups produces a stable composition that readily releases the boronic acid compound upon dissolution in aqueous media | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-09-19 | — | — | US | claimed |
| EP-1627880-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1312609-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050282742-A1 | Formulation of boronic acid compounds | Government of the USA, represented by the Secretary,Dept. of Health and Human Services (US) | 2005-12-22 | — | — | US | claimed |
| US-6958319-B2 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-10-25 | — | — | US | claimed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002059131-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | claimed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| US-6083903-A | REDUCE RATE OF DEGRADATION OF PROTEINS IN ANIMAL | LEUKOSITE, INC. (US) | 2000-07-04 | — | — | US | claimed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | claimed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282742-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | ITGB3 4554/4885ITGAV 4522/4885NTSR1 869/4885 |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | ITGB3 3002/4885ITGAV 3068/4885NTSR1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.